tiprankstipranks
Advertisement
Advertisement

AGIO Stock Latest News

Agios Pharmaceuticals price target raised to $52 from $46 at Citi
The FlyAgios Pharmaceuticals price target raised to $52 from $46 at Citi
13d ago
AGIO
Agios: Buy Rating Reiterated on Strong AQVESME Uptake and Pipeline Progress, Price Target Maintained at $46
PremiumRatings
Agios: Buy Rating Reiterated on Strong AQVESME Uptake and Pipeline Progress, Price Target Maintained at $46
13d ago
AGIO
Agios: Strong Mitapivat Launch and Growing Patient Uptake Drive Confident Buy Rating
PremiumRatings
Agios: Strong Mitapivat Launch and Growing Patient Uptake Drive Confident Buy Rating
13d ago
AGIO
Agios Pharmaceuticals price target raised to $55 from $52 at H.C. Wainwright
PremiumThe Fly
Agios Pharmaceuticals price target raised to $55 from $52 at H.C. Wainwright
13d ago
AGIO
Agios Pharmaceuticals reports Q2 EPS ($1.69), consensus ($1.66)
PremiumThe Fly
Agios Pharmaceuticals reports Q2 EPS ($1.69), consensus ($1.66)
14d ago
AGIO
AGIO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsAGIO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
16d ago
AGIO
Agios Pharmaceuticals: Buy Rating Reaffirmed with Unchanged $46 Price Target on Mitapivat Sickle Cell Catalyst and AQVESME Thalassemia Launch Momentum
Premium
Ratings
Agios Pharmaceuticals: Buy Rating Reaffirmed with Unchanged $46 Price Target on Mitapivat Sickle Cell Catalyst and AQVESME Thalassemia Launch Momentum
22d ago
AGIO
Agios Pharmaceuticals price target lowered to $52 from $54 at H.C. Wainwright
Premium
The Fly
Agios Pharmaceuticals price target lowered to $52 from $54 at H.C. Wainwright
22d ago
AGIO
Morning Movers: Equifax sinks following second quarter earnings
PremiumThe Fly
Morning Movers: Equifax sinks following second quarter earnings
23d ago
GM
DHI
Agios Pharmaceuticals down 13% at $34.75 on topline results from tebapivat trial
PremiumThe Fly
Agios Pharmaceuticals down 13% at $34.75 on topline results from tebapivat trial
23d ago
AGIO
Agios Pharmaceuticals announces topline results from tebapivat trial
PremiumThe Fly
Agios Pharmaceuticals announces topline results from tebapivat trial
23d ago
AGIO
Agios Pharmaceuticals rises 13.5%
PremiumThe Fly
Agios Pharmaceuticals rises 13.5%
1M ago
AGIO
Mitapivat’s Priority Review in Sickle Cell Disease Supports First-in-Class 2026 Launch, Long-Term Growth; Buy Rating and $54 Price Target Maintained
PremiumRatingsMitapivat’s Priority Review in Sickle Cell Disease Supports First-in-Class 2026 Launch, Long-Term Growth; Buy Rating and $54 Price Target Maintained
1M ago
AGIO
Leerink sees Priority Review designation as positive sign for Agios’ mitapivat
Premium
The Fly
Leerink sees Priority Review designation as positive sign for Agios’ mitapivat
1M ago
AGIO
H.C. Wainwright sees FDA Priority Review as positive signal for Agios’ mitapivat
Premium
The Fly
H.C. Wainwright sees FDA Priority Review as positive signal for Agios’ mitapivat
1M ago
AGIO
Agios Pharmaceuticals rises 12.9%
PremiumThe Fly
Agios Pharmaceuticals rises 12.9%
1M ago
AGIO
Agios Pharmaceuticals price target raised to $46 from $40 at BofA
PremiumThe Fly
Agios Pharmaceuticals price target raised to $46 from $40 at BofA
1M ago
AGIO
Agios Pharmaceuticals price target raised to $41 from $36 at Truist
PremiumThe Fly
Agios Pharmaceuticals price target raised to $41 from $36 at Truist
1M ago
AGIO
Agios Pharmaceuticals price target raised to $32 from $28 at RBC Capital
PremiumThe Fly
Agios Pharmaceuticals price target raised to $32 from $28 at RBC Capital
1M ago
AGIO
Agios Pharmaceuticals granted priority review for mitapivat sNDA
PremiumThe FlyAgios Pharmaceuticals granted priority review for mitapivat sNDA
1M ago
AGIO
Agios Pharma Shareholders Expand Equity Plan, Reelect Directors
Premium
Company Announcements
Agios Pharma Shareholders Expand Equity Plan, Reelect Directors
2M ago
8K
AGIO
Agios Targets Transfusion Burden in Sickle Cell Disease With New Phase 3 Bet on Mitapivat
Premium
Company Announcements
Agios Targets Transfusion Burden in Sickle Cell Disease With New Phase 3 Bet on Mitapivat
2M ago
AGIO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >